C. Wiesmann

发表

Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding

Christian Wiesmann, Ping Wu, M. Tessier-Lavigne, 2007, The EMBO journal.

The discovery of first-in-class drugs: origins and evolution

C. Wiesmann, J. Eder, R. Sedrani, 2014, Nature Reviews Drug Discovery.

In situ assembly of enzyme inhibitors using extended tethering

W. Delano, E. Gordon, Joni W. Lam, 2003, Nature Biotechnology.

High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries.

Frederic A. Fellouse, A. Koide, S. Koide, 2007, Journal of molecular biology.

Inhibition of Wnt signaling by Dishevelled PDZ peptides.

R. Hannoush, S. Sidhu, Yingnan Zhang, 2009, Nature chemical biology.

Crystal Structure of Murine Coronin-1

B. Appleton, Ping Wu, C. Wiesmann, 2005 .

Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition.

Sachdev S Sidhu, Christian Wiesmann, Frederic A. Fellouse, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor

Christian Wiesmann, S. Bass, M. Ultsch, 1999, Nature.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

Christian Wiesmann, Pamela Chan, Ping Wu, 2009, The Journal of clinical investigation.

De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling

Somasekar Seshagiri, L. Aravind, Eugene V. Koonin, 2004, Nature.

Nerve growth factor: structure and function

A. D. de Vos, C. Wiesmann, A. D. Vos, 2001, Cellular and Molecular Life Sciences CMLS.

CHAPTER 49 – The Mechanism of NGF Suggested by the NGF–TrkA-D5 Complex

C. Wiesmann, A. D. Vos, 2003 .

Crystal structure of NGF in complex with the ligand-binding domain of the TrkA receptor

B. Vos, M. Ultsch, C. Wiesmann, 1999 .

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

Gary Box, Paul Workman, Christian Wiesmann, 2008, Journal of medicinal chemistry.

Crystal structure of the complex between VEGF and a receptor-blocking peptide.

A. D. de Vos, B. Cunningham, H. Christinger, 1998, Biochemistry.

The Crystal Structure of Placental Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1*

A. D. de Vos, H. Christinger, G. Fuh, 2004, Journal of Biological Chemistry.

Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.

D. Sutherlin, C. Wiesmann, M. Mayeda, 2007, Bioorganic & medicinal chemistry letters.

Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity*

D. Sutherlin, W. Fairbrother, J. M. Elliott, 2006, Journal of Biological Chemistry.

The structural basis of Indisulam-mediated recruitment of RBM39 to the DCAF15-DDB1-DDA1 E3 ligase complex

V. Hornak, D. Bussiere, C. Wiesmann, 2019, bioRxiv.

A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.

Jennafer Dotson, Christian Wiesmann, Jason Drummond, 2009, Journal of medicinal chemistry.

Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab*

M. Ultsch, G. Fuh, Ping Wu, 2006, Journal of Biological Chemistry.

Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.

BinQing Wei, D. Sutherlin, L. Friedman, 2011, Journal of medicinal chemistry.

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.

D. Sutherlin, S. Sideris, L. Friedman, 2010, Journal of medicinal chemistry.

Human Memory B Cells Harbor Diverse Cross‐Neutralizing Antibodies against BK and JC Polyomaviruses

John M. Lindner, M. Scharenberg, C. Wiesmann, 2019, Immunity.

The three-dimensional structure of 6-phospho-beta-galactosidase from Lactococcus lactis.

G. Schulz, C. Wiesmann, W. Hengstenberg, 1995, Structure.

Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.

A. D'arcy, M. Mogi, C. Wiesmann, 2020, ACS medicinal chemistry letters.

CHAPTER 50 – The Mechanism of VEGFR Activation Suggested by the Complex of VEGF–flt1-D2

C. Wiesmann, A. D. Vos, 2003 .

Crystal structure of the HGF β-chain in complex with the sema domain of the Met receptor

C. Wiesmann, J. Stamos, 2005 .

Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT)

F. Supek, M. Barrett, H. Cheung, 2022, Journal of medicinal chemistry.

Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.

F. Sirockin, E. Valeur, C. Wiesmann, 2018, Bioorganic & medicinal chemistry letters.

Abstract DDT02-01: Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.

M. Belvin, E. Bradley, M. Ultsch, 2013 .

Targeted inhibition of the COP9 signalosome for treatment of cancer

E. Altmann, U. Hassiepen, M. Renatus, 2016, Nature Communications.

Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.

Andreas Lingel, Thomas M Weiss, Christian Wiesmann, 2009, Structure.

Variations on ligand–receptor complexes

C. Wiesmann, A. D. Vos, 2000, Nature Structural Biology.

Stabilizing Inactive Conformations of MALT1 as an Effective Approach to Inhibit Its Protease Activity

M. Renatus, C. Wiesmann, F. Villard, 2020 .

A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability.

Guy Georges, Elizabeth Blackwood, Christian Wiesmann, 2008, Journal of medicinal chemistry.

Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.

E. Bradley, BinQing Wei, J. Lesnick, 2013, Bioorganic & medicinal chemistry letters.

Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.

D. Sutherlin, S. Sideris, Leslie B. Lee, 2011, Bioorganic & medicinal chemistry letters.

Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.

BinQing Wei, D. Sutherlin, J. Lesnick, 2011, Journal of medicinal chemistry.

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.

A. D. de Vos, H. Christinger, G. Fuh, 1999, Journal of molecular biology.

Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor

Charles Eigenbrot, Christian Wiesmann, James A. Wells, 1997, Cell.

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

F. Supek, D. Caridha, Yen-Liang Chen, 2020, Journal of medicinal chemistry.

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Ariana Peck, Shiuh-Ming Luoh, Steve Price, 2013, Nature.

Structural determinants of MALT1 protease activity.

A. D'arcy, A. Bernardi, M. Renatus, 2012, Journal of molecular biology.

Crystal structure of the HGF β‐chain in complex with the Sema domain of the Met receptor

Christian Wiesmann, D. Kirchhofer, C. Wiesmann, 2004, The EMBO journal.

Putting two and two together: crystal structure of the FGF-receptor complex.

A. D. de Vos, C. Wiesmann, 1999, Structure.

Macrophage complement receptors and pathogen clearance

M. van Lookeren Campagne, E. Brown, C. Wiesmann, 2007, Cellular microbiology.

Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex

V. Hornak, D. Bussiere, C. Wiesmann, 2019, Nature Chemical Biology.

Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering

Jianping Yin, J. Bazan, L. Comps-Agrar, 2012, Proceedings of the National Academy of Sciences.

Comparative Structural Analysis of the Erbin PDZ Domain and the First PDZ Domain of ZO-1

Walter Hunziker, Sachdev S Sidhu, Christian Wiesmann, 2006, Journal of Biological Chemistry.

A structure-based database of antibody variable domain diversity.

C. J. Bond, S. Sidhu, C. Wiesmann, 2005, Journal of molecular biology.

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

F. Peale, L. Rangell, G. Fuh, 2007, Proceedings of the National Academy of Sciences.

Ligand-binding sites in Ig-like domains of receptor tyrosine kinases

A. D. de Vos, Y. Muller, C. Wiesmann, 2000, Journal of Molecular Medicine.

Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and TrkC.

S. Bass, M. Ultsch, A. D. de Vos, 1999, Journal of molecular biology.

Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.

M. Champe, A. D. de Vos, N. Skelton, 1999, Journal of molecular biology.

The crystal structure of murine coronin-1: a regulator of actin cytoskeletal dynamics in lymphocytes.

B. Appleton, Ping Wu, C. Wiesmann, 2006, Structure.

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Thomas M. Smith, N. Gradoux, Jian Ding, 2020, Journal of medicinal chemistry.

Cryo-EM in drug discovery: achievements, limitations and prospects

Claudio Ciferri, Jean-Paul Renaud, Ashwin Chari, 2018, Nature Reviews Drug Discovery.

A small-molecule inhibitor of C5 complement protein

M. Schirle, Mitsunori Kato, G. Michaud, 2019, Nature Chemical Biology.

A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis

M. van Lookeren Campagne, P. Hass, L. Rangell, 2007, The Journal of experimental medicine.

Structure of C3b in complex with CRIg gives insights into regulation of complement activation

P. Hass, Jianping Yin, W. Fairbrother, 2006, Nature.

Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement*

M. van Lookeren Campagne, P. Hass, Jianping Yin, 2009, Journal of Biological Chemistry.

Crystal Structure of Procaspase-1 Zymogen Domain Reveals Insight into Inflammatory Caspase Autoactivation*S⃞

J. M. Elliott, C. Wiesmann, J. Scheer, 2009, Journal of Biological Chemistry.

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

Franklin Peale, David Kan, Christian Wiesmann, 2009, Science.

The development of peptide-based tools for the analysis of angiogenesis.

Judith E. Flores, K. Deshayes, Simon-Peter Williams, 2011, Chemistry & biology.

Inhibiting Alternative Pathway Complement Activation by Targeting the Factor D Exosite*

Jeremy Murray, Christian Wiesmann, Ping Wu, 2012, The Journal of Biological Chemistry.

Allosteric inhibition of protein tyrosine phosphatase 1B

Wang Shen, Daniel A Erlanson, Christian Wiesmann, 2004, Nature Structural &Molecular Biology.

Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains*

C. J. Bond, S. Sidhu, B. Appleton, 2008, Journal of Biological Chemistry.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases

Thomas M. Smith, F. Sirockin, B. Gerhartz, 2019, Proceedings of the National Academy of Sciences.

The Mechanism of VEGFR Activation by VEGF

C. Wiesmann, 2010 .

Convergent and Divergent Ligand Specificity among PDZ Domains of the LAP and Zonula Occludens (ZO) Families*

Walter Hunziker, Sachdev S. Sidhu, Christian Wiesmann, 2006, Journal of Biological Chemistry.

Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.

M. Gill, G. Médard, E. Gancia, 2015, Journal of medicinal chemistry.

A structural portrait of the PDZ domain family.

D. Gfeller, S. Sidhu, Yingnan Zhang, 2014, Journal of molecular biology.

The Mechanism of NGF Signaling Suggested by the p75 and TrkA Receptor Complexes

J. Bazan, C. Wiesmann, 2010 .

Variations on ligand-receptor complexes.

C. Wiesmann, A. D. Vos, 2000 .

A role of macrophage complement receptor CRIg in immune clearance and inflammation.

M. van Lookeren Campagne, C. Wiesmann, Jeannie Q. He, 2008, Molecular immunology.

Structure of neprilysin in complex with the active metabolite of sacubitril

A. D'arcy, C. Wiesmann, F. Villard, 2016, Scientific Reports.

Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain

S. Sidhu, Yingnan Zhang, B. Appleton, 2007, Protein science : a publication of the Protein Society.

Crystal structures and mechanism of 6-phospho-beta-galactosidase from Lactococcus lactis.

G. Schulz, C. Wiesmann, W. Hengstenberg, 1997, Journal of molecular biology.

Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor β-Chain in Met Binding and Signaling*

D. Kirchhofer, C. Eigenbrot, C. Wiesmann, 2004, Journal of Biological Chemistry.

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.

Daniel A Erlanson, Christian Wiesmann, W. Delano, 2002, Journal of medicinal chemistry.

Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.

P. Savy, Steve Price, M. Belvin, 2012, Journal of medicinal chemistry.

Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.

C. Wiesmann, M. Mayeda, C. Quan, 2007, Biochemistry.

Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2‐Pro1‐cleaving specificity

W. Fairbrother, C. Wiesmann, Victoria C. Pham, 2006, FEBS letters.

Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3

Stephen L. Sazinsky, S. Sidhu, Steven T. Runyon, 2007, Protein science : a publication of the Protein Society.

Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor.

S. Sidhu, C. Wiesmann, Xiaolei Ma, 2013, Journal of molecular biology.

Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.

Ivana Yen, S. Sideris, S. Malek, 2014, Bioorganic & medicinal chemistry letters.

Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.

P. Savy, Steve Price, M. Ultsch, 2014, Bioorganic & medicinal chemistry letters.

Limitations to the application of molecularly targeted cancer therapies are the inability to accurately match patient with effective treatment and the absence of a prompt readout of posttreatment response

Judith E. Flores, K. Deshayes, Simon-Peter Williams, 2011 .

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.

D. Dornan, S. Marsters, A. Ashkenazi, 2009, The Journal of clinical investigation.

On the edge of validation--cancer protease fibroblast activation protein.

D. Sutherlin, C. Wiesmann, C. Quan, 2008, Mini reviews in medicinal chemistry.

Inhibition of Wnt signaling by Dishevelled PDZ peptides.

R. Hannoush, S. Sidhu, Yingnan Zhang, 2009, Nature chemical biology.

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

F. Peale, G. Fuh, B. Appleton, 2009, Science.

Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.

B. Pan, C. Wiesmann, Andreas Lingel, 2009, Structure.

Improving Therapeutic Efficacy of a Complement Receptor by Structure-based Affinity Maturation

M. van Lookeren Campagne, R. Kelley, L. Diehl, 2009, The Journal of Biological Chemistry.

Supplemental Data Structure of IL-33 and Its Interaction with the ST 2 and IL-1 RAcP Receptors — Insight into the Heterotrimeric IL-1 Signaling Complexes

Andreas Lingel, Christian Wiesmann, Thomas M. Weiss, 2009 .